Showing 638 results for "cancer "

IkT-001Pro for Multiple Sclerosis

IkT-001Pro is a novel formulation being developed by Inhibikase Therapeutics for the treatment of progressive multifocal leukoencephalopathy (PML), one of the major complications of multiple sclerosis (MS) caused by the use of therapies that alter the immune system. How ikT-001Pro works PML is…

Novel Antibody Drug Candidate From Chinese Drug Developer Shows Promise For Treating MS

MicroConstants China, Inc., a company that provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis, and age related macular degeneration…

Multiple Sclerosis Risk Does not Increase with HPV Vaccine According to Study

Human papillomavirus (HPV) vaccination can help protect against several health problems, including cervical cancers in women. Some reports have raised concerns however, that the vaccine might actually increase the risk of developing multiple sclerosis. A study entitled “Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other…

Scientists Block Multiple Sclerosis in Mice Using Estrogen-Like Drug

A team of researchers at the University of California, Riverside, along with other collaborators, have identified a drug associated with estrogen, indazole chloride (Ind-Cl), that blocks the effects of multiple sclerosis (MS). The findings were reported December 1st in the Proceedings of the National Academy of Sciences. MS…

Genzyme’s Lemtrada Approved by the FDA

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…

Roche Turns to MS Research on Agreement with Versant Ventures

The Swiss pharmaceutical company Roche recently announced a partnership agreement with California-based Inception Sciences and venture capital firm Versant Ventures. The three companies will work together to form a new company, Inception 5, which will be dedicated mostly to the development of therapies for multiple sclerosis. Inception 5’s research will focus…